Christopher E. Barbieri

Christopher E. Barbieri

Auto-generated profile, based on publicly available information

Christopher E. Barbieri

Department of Urology, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cell
Verified
Journal Article
Closed access
AAAdam Abeshouse
Adam Abeshouse
JAJaeil Ahn
Jaeil Ahn
RARehan Akbani
Rehan Akbani
AAAdrian Ally
Adrian Ally
SASamirkumar Amin
Samirkumar Amin
EZErik Zmuda
Erik Zmuda

20 May 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBChristopher E Barbieri
Christopher E Barbieri
SBSylvan C Baca
Sylvan C Baca
MLMichael S Lawrence
Michael S Lawrence
FDFrancesca Demichelis
Francesca Demichelis
MBMirjam Blattner
Mirjam Blattner
LGLevi A Garraway
Levi A Garraway
Levi Garraway and colleagues report exome sequencing of 112 prostate adenocarcinomas and matched normal tissues. They identify novel recurrent mutations in several genes, including MED12, FOXA1 and SPOP. They find that tumors harboring SPOP mutations lack the TMPRSS2-ERG fusion or other ETS rearrangements, supporting the hypothesis that SPOP mutation is an early driver event in prostate tumorigenesis. Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year1. Overtreatment of indolent disease also results in significant morbidity2. Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21)3,4 and PTEN (10q23)5,6, gains of AR (the androgen receptor gene)7,8 and fusion of ETS family transcription factor genes with androgen-responsive promoters9,10,11. Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis12,13 but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6–15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.

1 April 2013 in Cell
Verified
Journal Article
Closed access
SBSylvan C. Baca
Sylvan C. Baca
DPDavide Prandi
Davide Prandi
MLMichael S. Lawrence
Michael S. Lawrence
JMJuan Miguel Mosquera
Juan Miguel Mosquera
ARAlessandro Romanel
Alessandro Romanel
LGLevi A. Garraway
Levi A. Garraway

14 August 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
XDXiangpeng Dai
Xiangpeng Dai
WGWenjian Gan
Wenjian Gan
XLXiaoning Li
Xiaoning Li
SWShangqian Wang
Shangqian Wang
WZWei Zhang
Wei Zhang
WWWenyi Wei
Wenyi Wei
Recurrent mutations in SPOP-encoding a Cullin 3-based E3 ubiquitin ligase- in prostate cancer disrupt the recognition and degradation of ubiquitination substrates, including BET proteins. Consequently, stability of BET proteins is enhanced and this increases the resistance to BET inhibitors in SPOP-mutant prostate tumors. These results, together with those in Janouskova et al. and Zhang et al., uncover a novel non genetic mechanism of resistance to BET inhibition involving cancer type-specific mutations in SPOP, and support the evaluation of SPOP mutations to inform the administration of BET inhibitors in the clinic. The bromodomain and extraterminal (BET) family of proteins comprises four members—BRD2, BRD3, BRD4 and the testis-specific isoform BRDT—that largely function as transcriptional coactivators1,2,3 and play critical roles in various cellular processes, including the cell cycle, apoptosis, migration and invasion4,5. BET proteins enhance the oncogenic functions of major cancer drivers by elevating the expression of these drivers, such as c-Myc in leukemia6,7, or by promoting the transcriptional activities of oncogenic factors, such as AR and ERG in prostate cancer8. Pathologically, BET proteins are frequently overexpressed and are clinically linked to various types of human cancer5,9,10; they are therefore being pursued as attractive therapeutic targets for selective inhibition in patients with cancer. To this end, a number of bromodomain inhibitors, including JQ1 and I-BET, have been developed11,12 and have shown promising outcomes in early clinical trials. Although resistance to BET inhibitors has been documented in preclinical models13,14,15, the molecular mechanisms underlying acquired resistance are largely unknown. Here we report that cullin-3SPOP earmarks BET proteins, including BRD2, BRD3 and BRD4, for ubiquitination-mediated degradation. Pathologically, prostate cancer–associated SPOP mutants fail to interact with and promote the degradation of BET proteins, leading to their elevated abundance in SPOP-mutant prostate cancer. As a result, prostate cancer cell lines and organoids derived from individuals harboring SPOP mutations are more resistant to BET-inhibitor-induced cell growth arrest and apoptosis. Therefore, our results elucidate the tumor-suppressor role of SPOP in prostate cancer in which it acts as a negative regulator of BET protein stability and also provide a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer bearing SPOP mutations.

1 October 2013 in European Urology
Verified
Journal Article
Closed access
CBChristopher E. Barbieri
Christopher E. Barbieri
CBChris H. Bangma
Chris H. Bangma
ABAnders Bjartell
Anders Bjartell
JCJames WF Catto
James WF Catto
ZCZoran Culig
Zoran Culig
MRMark A. Rubin
Mark A. Rubin

4 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CGChuandong Geng
Chuandong Geng
BHBin He
Bin He
LXLimei Xu
Limei Xu
CBChristopher E. Barbieri
Christopher E. Barbieri
VEVijay Kumar Eedunuri
Vijay Kumar Eedunuri
NMNicholas Mitsiades
Nicholas Mitsiades
The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic “master regulators” of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.